Introduction {#S1}
============

High-resolution oesophageal manometry (HREM) is used to diagnose oesophageal motility disorders. However, it has been noted that patient symptoms do not correlate well with changes noted during HREM studies \[[@ref1]\]. It is not uncommon to find a normal study or the presence of minor peristaltic defects -- ineffective oesophageal motility and fragmented peristalsis -- in symptomatic patients. The clinical significance of such findings in symptomatic patients remains unclear.

Aim {#S2}
===

The present study was undertaken to determine the clinical presentation of patients with normal manometry and minor peristaltic disorders. The patients were followed up at regular intervals for 2 years to determine the response to treatment and outcomes in these cases.

Material and methods {#S3}
====================

The present study is a prospective cohort study. Patients between 18 and 80 years of age, who were referred to the author for HREM evaluation between January 2014 and April 2016, were initially enrolled. Oesophageal manometry was performed in a supine position with 10 × 5 ml water swallows and reported using Chicago Classification (CC) v 3.0 by a single observer. Those tracings which had been reported using CC 2.0 were reinterpreted using the newer classification.

Exclusion criteria: Unwilling to participate, age \< 18 years, previous upper gastrointestinal surgery, prior dilation or myotomy, oesophageal stricture, technically inadequate study, and major motility disorders or EGJ outflow obstruction as per CC v 3.0.

Case records were reviewed for clinical history, endoscopic findings, and treatment offered ([Figure 1](#F1){ref-type="fig"}). The patients were classified into two groups: those with normal manometry (Gp1) and those with minor peristaltic defects (Gp2). Study subjects were followed up at 6 months, 12 months, and 24 months from the date of initial HREM study. This was done either by at least two direct consultations (48 cases) or telephonic interview (8 cases). Details of drug use (type and frequency), symptom control (improvement/no change/worsening), and requirement of anti-reflux procedures (endoscopic/surgical) in both groups were obtained.

![Study methodology](PG-15-40086-g001){#F1}

Written, informed consent was taken at the time of enrolment from each patient. The study was approved by the local Ethics Committee and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.

Statistical analysis {#S3_1}
--------------------

Descriptive statistics were used to characterise the patient cohort. Comparison between patient groups was made by using the χ^2^ test. A *p*-value of \< 0.05 was considered significant.

Results {#S4}
=======

Fifty-six patients formed the study cohort. The median age was 42 years (range: 21--78 years), and males outnumbered the females (48, 72% vs. 18, 28%). Normal manometry (Gp1) was noted in 35 (62.5%) and minor peristaltic disorders (Gp2) in 21 (37.5%) patients. Upper gastrointestinal endoscopy was normal in 48 cases, while 8 showed low-grade reflux esophagitis (Los Angeles grade A).

[Table I](#T1){ref-type="table"} shows the indications for HREM study in the study cohort. The patients in the two groups were comparable in terms of symptoms at presentation. The details of drugs prescribed at the initial presentation in the two groups are shown in [Table II](#T2){ref-type="table"}. The majority of the cases were prescribed proton pump inhibitors ± prokinetic agents. Six patients were prescribed additional sodium alginate, and one patient was given pyridostigmine for large breaks in peristalsis.

###### 

Indications of HREM study in the study cohort

  Symptoms[\*](#TF1-1){ref-type="table-fn"}                   Gp1 (*n* = 35)   Gp2 (*n* = 21)   *P*-value
  ----------------------------------------------------------- ---------------- ---------------- -----------
  GERD (heartburn/regurgitation/extra-oesophageal symptoms)   23 (65.7%)       15 (71.4%)       0.94
  Chest pain                                                  9 (25.7%)        4 (19%)          
  Dysphagia                                                   5 (14.3%)        3 (14.3%)        
  Others (belching/bloating/epigastric pain)                  12 (34.3%)       8 (38.1%)        

Some patients had combination of symptoms.

###### 

Treatment offered at initial presentation in the study cohort

  Drugs prescribed                                                      Gp1 (*n* = 35)   Gp2 (*n* = 21)   *P*-value
  --------------------------------------------------------------------- ---------------- ---------------- -----------
  Proton pump inhibitors alone                                          12 (34.3%)       10 (47.6%)       0.15
  Prokinetics alone                                                     11 (31.4%)       1 (4.8%)         
  Combination of the above two groups                                   12 (34.3%)       9 (42.9%)        
  Others (along with the above), e.g. sodium alginate, pyridostigmine   4 (11.4%)        3 (14.3%)        

[Table III](#T3){ref-type="table"} shows the symptom profile and medication use in the study cohort at 6, 12, and 24 months follow-up. There was improvement in symptoms and a corresponding decrease in the everyday intake of medicines in both groups. None of the patients reported worsening while on treatment, and none required surgery. However, nearly one fourth of cases (13/56, 23.2%) did not notice any significant change in their symptoms at 2 years. Seventeen (30.3%) cases were continuing drugs on an everyday basis even at 2 years follow-up. A few patients also reported the use of alternative medications like homeopathy/Ayurveda for symptom relief on follow-up. There were no significant differences in the symptom profile and drug use in patients with normal peristalsis and those with minor peristaltic disorders at various time periods during follow-up. However, a greater number of cases in Gp 2 reported symptomatic improvement at the end of 1 year (76.2% vs. 68.5%) and 2 years (85.4% vs. 71.4%).

###### 

Details of follow-up

  Parameters                       Gp1 (*n* = 35)   Gp2 (*n* = 21)   *P*-value
  -------------------------------- ---------------- ---------------- -----------
  6-month follow-up:                                                 
  Symptoms:                                                          0.83
  Improved                         21 (60%)         12 (57.1%)       
  No change                        14 (40%)         9 (42.9%)        
  Worsened                         0.0              0.0              
  Medications:                                                       0.29
  Continuing every day             12 (34.3%)       12 (57%)         
  On demand                        20 (57.1%)       8 (38.1%)        
  Stopped                          3 (8.5%)         1 (4.8%)         
  Use of alternative medications   2 (5.7%)         3 (14.3%)        
  Requirement of surgery           Nil              Nil              --
  12-month follow-up:                                                
  Symptoms:                                                          0.54
  Improved                         24 (68.5%)       16 (76.2%)       
  No change                        11 (31.5%)       5 (23.8%)        
  Worsened                         0.0              0.0              
  Medications:                                                       0.12
  Continuing every day             10 (28.6%)       12 (57.2%)       
  On demand                        21 (60%)         6 (28.6%)        
  Stopped                          4 (11.4%)        3 (14.3%)        
  Use of alternative medications   3 (8.5%)         3 (14.3%)        
  Requirement of surgery           Nil              Nil              --
  24-month follow-up:                                                
  Symptoms:                                                          0.17
  Improved                         25 (71.4%)       18 (85.7%)       
  No change                        10 (28.6%)       3 (14.3%)        
  Worsened                         0.0              0.0              
  Medications:                                                       0.18
  Continuing every day             8 (22.9%)        9 (42.9%)        
  On demand                        25 (71.4%)       9 (42.9%)        
  Stopped                          2 (5.7%)         3 (14.3%)        
  Use of alternative medications   3 (8.5%)         3 (14.3%)        
  Requirement of surgery           Nil              Nil              --

Discussion {#S5}
==========

The present study was done to determine the clinical significance of normal manometry and minor manometric abnormalities in symptomatic patients during HREM studies. It was observed that patients with these disorders had similar clinical presentation and were prescribed similar drug treatment. Over a 2-year follow-up there was symptomatic improvement in three fourths of cases, with no requirement of therapeutic endoscopic or surgical intervention. Moreover, there were no significant differences between the two groups, Gp1 and Gp 2, suggesting that these findings have "benign" outcome. Improvement of symptoms was higher in patients with minor peristaltic disorders at 1-year and 2-year follow-up. This is similar to observations in an earlier study \[[@ref2]\].

Various authors have investigated the significance of nonspecific oesophageal motility changes. Achem *et al*. \[[@ref3]\], using conventional manometry, followed up 23 patients of non-specific oesophageal dysmotility and chest pain. The authors noted that follow-up manometric studies were normal in 29% and manometric changes persisted in 57% of the patients. In 3 (14%) patients, the pattern evolved into diffuse oesophageal spasm. The study highlighted that mechanisms other than disturbed oesophageal motility may be responsible for the symptoms in these individuals. Similar findings were noted in a study from Israel, in which the majority of the patients with nonspecific oesophageal dysmotility showed improvement on follow-up, and only 6% progressed to achalasia \[[@ref4]\]. Ravi *et al*. reported long-term outcomes of patients with normal and minor motility disorders \[[@ref2]\]. They noted that these patients rarely required interventions related to oesophageal dysfunction during long-term follow-up. It should be noted that this study was done using CC2.0, and 10 cases of nutcracker oesophagus were included in the study cohort. With refinement in reporting using CC, the major motor disorders are now well characterised, and detection is better compared to conventional manometry.

The findings of the present study and above-mentioned data question the significance and clinical relevance of detecting normal manometry and minor peristaltic disorders in HREM studies in symptomatic patients. It is well documented that these changes may be noted in asymptomatic healthy adults as well \[[@ref5]\]. Moreover, management strategies in both groups remain similar. Treatment is usually directed towards management of reflux, and there are no effective treatments to restore impaired oesophageal smooth muscle contractility \[[@ref6]\].

When patients with normal manometry and minor peristaltic disorders behave in similar way, do we really need these additional classifications? The answer is inconclusive because a few studies have noted that the presence of large breaks is linked to bolus transit failure and fragmented peristalsis to reflux symptoms \[[@ref7], [@ref8]\]. The future CC needs to address and clarify these issues.

Limitations: Small sample size; short, 2-year follow-up; no use of videofluoroscopy or 24-hour pH study; no repeat HREM study during follow-up; small number of patients in subgroups of minor peristaltic disorders, i.e. ineffective oesophageal motility and fragmented peristalsis

Conclusions {#S6}
===========

Patients with normal and minor oesophageal motor function abnormalities do not worsen over time, and the majority of them show good response to treatment. Those with minor motor function abnormalities are more likely to be better at 2-year follow-up than those with normal studies.
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